Palisade Bio Q2 net loss widens on higher R&D costs

Palisade Bio

10/08/2026 21:28

Overview
U.S. biopharmaceutical firm's Q2 net loss widened as R&D and admin expenses increased
Company recognized license revenue from milestone achievement in co-development agreement
Cash position expected to fund operations through Phase 2 trial efficacy readouts in 2027 and 2028

Outlook
Company expects to start Phase 2 ASCENTRA-UC trial in 2H 2026; efficacy readout in 2H 2027
IND for Phase 2 ASCENTRA-CD trial expected 2H 2026; trial start targeted for 1Q 2027
Company expects cash resources to fund operations through key Phase 2 clinical readouts

Result Drivers
INCREASED R&D SPENDING - Higher research and development expenses driven by employee-related costs, stock-based compensation, and expanded PALI-2108 program activities
MILESTONE LICENSE REVENUE - License revenue recognized from milestone achievement in co-development agreement with Newsoara

Company press release: ID:nGNX5gybpD

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Loss Per Share
 
$0.05
 
Q2 Net Loss
 
$10.57 mln
 
Q2 Operating Expenses
 
$12.2 mln
 
Q2 Operating Income
 
-$11.7 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Palisade Bio Inc is $8.00, about 279.1% above its August 7 closing price of $2.11

Reuters Recommended Reads
Aug 10 - Oruka Therapeutics Q2 net loss widens on higher R&D costs
Aug 10 - Olema Pharmaceuticals Q2 net loss widens on higher clinical trial spending
Aug 10 - Fractyl Health Q2 net loss narrows on lower expenses

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)